NPS Pharmaceuticals to Present at Deutsche Bank BioFEST Conference

2012 Deutsche Bank BioFEST Conference

BEDMINSTER, N.J.--()--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the 2012 Deutsche Bank BioFEST Conference in Boston on Tuesday, December 4, 2012 at 10:10 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors’ calendar of events page on the NPS website at http://www.npsp.com/calendar.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. NPS is advancing two late-stage registration programs. A New Drug Application is undergoing FDA review for Gattex® (teduglutide) as a treatment for adults with short bowel syndrome (SBS) and a Biologic License Application is being prepared for Natpara® (rhPTH[1-84]) in adult hypoparathyroidism. NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Nycomed, a Takeda company.

Contacts

NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335

Sharing

Contacts

NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335